Abstract
A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.
| Original language | English |
|---|---|
| Pages (from-to) | 78-81 |
| Number of pages | 4 |
| Journal | Regional Cancer Treatment |
| Volume | 7 |
| Issue number | 2 |
| State | Published - 1995 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pharmacology
Cite this
Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. / Loggie, Brian W.; Sterchi, J. M.; Rogers, A. T.; Lentz, S.; Holmesle, H.; Charles, D.; Sundberg, D.
In: Regional Cancer Treatment, Vol. 7, No. 2, 1995, p. 78-81.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers
AU - Loggie, Brian W.
AU - Sterchi, J. M.
AU - Rogers, A. T.
AU - Lentz, S.
AU - Holmesle, H.
AU - Charles, D.
AU - Sundberg, D.
PY - 1995
Y1 - 1995
N2 - A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.
AB - A limited phase I pilot study of intraperitoneal hyperthermic chemotherapy (IPHC) in patients with carcinomatosis peritonei is reported. Seven adult patients with extensive carcinomatosis peritonei from gastrointestinal (n=6) or ovarian (n=1) primary cancer confined to the abdominopelvic cavity were treated. Bowel resection with anastomosis was done in 4 patients, and all had gross residual disease. The heated peritoneal perfusion with Mitomycin C (MMC), 30 mg, lasted 2-hours. No postoperative deaths, wound infections, subphrenic abscesses, or bowel leaks occurred. Two patients had self-limited serous wound leaks. Grade 3 neutropenia and grade 1 thrombocytopenia occurred; in one patient. Patients were discharged 9 to 23 days (median 11 days) postoperatively and median survival was 123 days (45 to 185). Malignant ascites present in 5 patients pre-IPHC was no longer present in 3 of those patients at discharge. Maximal mean MMC levels (μg/ml±SD; n=5) in perfusion fluid were 5.33±1.37, falling to 2.30±1.34 at 2 hours. Based on this limited trial, IPHC appears technically feasible, relatively safe, and warrants further clinical study in the treatment of disseminated intraperitoneal malignant disease.
UR - http://www.scopus.com/inward/record.url?scp=0028837966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028837966&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028837966
VL - 7
SP - 78
EP - 81
JO - Regional Cancer Treatment
JF - Regional Cancer Treatment
SN - 0935-0411
IS - 2
ER -